| 1 |
Gruneau L, Ekstedt M, Kechagias S, Henriksson M. Disease Progression Modeling for Economic Evaluation in Nonalcoholic Fatty Liver Disease-A Systematic Review. Clin Gastroenterol Hepatol 2023;21:283-98. [PMID: 34757199 DOI: 10.1016/j.cgh.2021.10.040] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 4.0] [Reference Citation Analysis]
|
| 2 |
Herring WL, Gould IG, Wittrup-Jensen V, Ertle J, Kuti E, Wolowacz S. Evaluation of emerging NASH therapies: the impact of treatment efficacy profiles on long-term health outcomes. J Comp Eff Res 2022;11:1349-63. [PMID: 36317935 DOI: 10.2217/cer-2021-0194] [Reference Citation Analysis]
|
| 3 |
Choo BP, Goh GB, Chia SY, Oh HC, Tan NC, Tan JYL, Ang TL, Bee YM, Wong YJ. Non-alcoholic fatty liver disease screening in type 2 diabetes mellitus: A cost-effectiveness and price threshold analysis. Ann Acad Med Singap 2022;51:686-694. [DOI: 10.47102/annals-acadmedsg.2022284] [Reference Citation Analysis]
|
| 4 |
Andersson A, Kelly M, Imajo K, Nakajima A, Fallowfield JA, Hirschfield G, Pavlides M, Sanyal AJ, Noureddin M, Banerjee R, Dennis A, Harrison S. Clinical Utility of Magnetic Resonance Imaging Biomarkers for Identifying Nonalcoholic Steatohepatitis Patients at High Risk of Progression: A Multicenter Pooled Data and Meta-Analysis. Clin Gastroenterol Hepatol 2022;20:2451-2461.e3. [PMID: 34626833 DOI: 10.1016/j.cgh.2021.09.041] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 7.0] [Reference Citation Analysis]
|
| 5 |
Javanbakht M, Fishman J, Moloney E, Rydqvist P, Ansaripour A. Early Cost-Effectiveness and Price Threshold Analyses of Resmetirom: An Investigational Treatment for Management of Nonalcoholic Steatohepatitis. Pharmacoecon Open 2023;7:93-110. [PMID: 36104546 DOI: 10.1007/s41669-022-00370-2] [Reference Citation Analysis]
|
| 6 |
Younossi Z, Aggarwal P, Shrestha I, Fernandes J, Johansen P, Augusto M, Nair S. The burden of non-alcoholic steatohepatitis: A systematic review of health-related quality of life and patient-reported outcomes. JHEP Reports 2022. [DOI: 10.1016/j.jhepr.2022.100525] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 4.0] [Reference Citation Analysis]
|
| 7 |
Witkowski M, Moreno SI, Fernandes J, Johansen P, Augusto M, Nair S. The Economic Burden of Non-Alcoholic Steatohepatitis: A Systematic Review. Pharmacoeconomics 2022;40:751-76. [PMID: 35789987 DOI: 10.1007/s40273-022-01140-y] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
|
| 8 |
Tran C, Kim JJ, Feld JJ, Wong WW. Cost-effectiveness of obeticholic acid for the treatment of non-alcoholic steatohepatitis: An early economic evaluation. CanLivJ 2021;4:360-9. [DOI: 10.3138/canlivj-2021-0011] [Reference Citation Analysis]
|
| 9 |
Tapper EB, Chhatwal J. We are Not Meeting the Needs of Pharmacoeconomic Models of Nonalcoholic Steatohepatitis, But We Can. Pharmacoeconomics 2020;38:427-9. [PMID: 32086769 DOI: 10.1007/s40273-020-00892-9] [Reference Citation Analysis]
|
